Juarterly Compliance Report on Corporate Governance

Name of the Company:

PARMAX PHARMA LIMITED.

Quarter ending on: 31st December 2013

Particulars	Clause of Listing agreement	Compliance Status Yes/No	Remarks
	49 I		
Board of Directors	49 I 49(IA)	Yes	
A) Composition of Board	49(IA) 49 (IB)	Yes	
3) Non-executive Directors' compensation & disclosures			
C) Other provisions as to Board and Committees	49 (IC)	Yes	
D) Code of Conduct	- (49 (ID)	Yes	
	49 (II)		
I. Audit Committee	49 (IIA)	Yes	
A) Qualified & Independent Audit	49 (117)	105	
Committee		Yes	
B) Meeting of Audit Committee	40 (IID)	Yes	
C) Powers of Audit Committee 49 (IIC)		Yes	
D) Role of Audit Committee	49 II(D)		
E) Review of Information by Audit	49 (IIE)	Yes	
II. Subsidiary Companies	49 (III)	N.A.	
V. Disclosures	49 (IV)	8	
A) Basis of related party transactions	49 (IV A)	Yes 🖌	
B) Disclosure of Accounting Treatment	49 (IV B)	Yes	
C) Board Disclosures	49 (IV C)	Yes	
(D) Proceeds from public issues, rights	49 (IV D)	N.A.	
issues, preferential issues etc.			
(E) Remuneration of Directors	49 (IV E)	Yes	A disclosure on the remuneration of
(E) Remuneration of Directors			Directors would be a part of section
			on Corporate Governance in the
			Annual Report of the Company for
			the year ended 31 st March, 2014.
	49 (IV F)	Yes	Management Discussion & other
(F) Management	4) (111)	100	Analysis would be a part of Annual
			Report of the Company for the year
			ended 31 st March, 2014.
	49 (IV G)	Yes	" Will be complied with at the
(G) Shareholders	49 (1 V O)	165	AGM"
ano (CPO Contification	49.(V)	Yes	CEO/CFO certification would be
V.CEO/CFO Certification	12.(1)		apart of Annual Report of the
			Company for the year ended
			31 st March, 2014.
	49 (VI)	Yes	Report of Corporate Governance
VI. Report on Corporate Governance			would be apart of Annual Report of
			the Company for the year ended
			31 st March, 2014.
	10 (VIII)	Yes	Compliance Certificate from
VII. Compliance	49 (VII)	105	Auditors would be apart of Annua
			Report of the Company for the yea
			ended 31 st March, 2014
			Parmax Pharma Ltt

D. Graval